Citations

Mayo Clinic

Showing 10 of 108537 citations.

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
Wright, R. Scott , Köenig, Wolfgang , Landmesser, Ulf , Leiter, Lawrence A. , Vikarunnessa, Sheikh, Lesogor, Anastasia, Maheux, Pierre, Talloczy, Zsolt, Zang, Xiao , Schwartz, Gregory G. , Ray, Kausik K. , Koenig, Wolfgang , Leiter, Lawrence A , Schwartz, Gregory G , Landmesser, Ulf , Wright, R Scott , Ray, Kausik K , Raal, Frederick J.

Cardiovascular Research | May 15, 2024 | Volume: 120 | Issue: 12 | Pages: 1400-1410

10.1093/cvr/cvae109 | PMID 38753448 Get It

Abstract Aims Data describing the long-term efficacy and tolerability of inclisiran are limited. This was explored in ORION-8, an open-label extension of preceding Phase 2 and Phase 3 placebo-controlled and open-label extension trials. Methods and results Following completion of the parent trial, adult patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent, or heterozygous familial hypercholesterolaemia received open-label inclisiran twice yearly (after initial and 3-month doses) until Day 990, followed by an end-of-study visit at Day 1080 or ≥ 90 days after the last dose. The study endpoints included the proportion of patients achieving pre-specified low-density lipoprotein cholesterol (LDL-C) goals [ASCVD: < 1.8 mmol/L (< 70 mg/dL); ASCVD risk equivalent: < 2.6 mmol/L (< 100 mg/dL)], percentage and absolute changes in LDL-C at end-of-study, and safety of inclisiran. Of 3274 patients, 2446 (74.7%) were followed until end-of-study. Mean age was 64.9 ± 9.9 years, 82.7% (n = 2709) had ASCVD, and mean baseline LDL-C was 2.9 ± 1.2 mmol/L. Mean cumulative exposure to inclisiran (including parent trials) was 3.7 years; maximum exposure was 6.8 years. With inclisiran, 78.4% [95% confidence interval (CI): 76.8, 80.0] of patients achieved pre-specified LDL-C goals and mean percentage change in LDL-C was −49.4% (95% CI: −50.4, −48.3). No attenuation of LDL-C lowering over time was observed. Treatment-emergent adverse events at injection site (all mild/moderate) occurred in 5.9% of the patients. Inclisiran-associated anti-drug antibodies were infrequent (5.5%) and had no impact on the efficacy or safety of inclisiran. No new safety signals were identified. Conclusion In the largest and longest follow-up to date with >12 000 patient-years exposure, inclisiran demonstrated consistent and effective LDL-C lowering with a favourable long-term safety and tolerability profile. Trial Registration number ClinicalTrials.gov identifier: NCT03814187
PAPP-A as a Potential Target in Thyroid Eye Disease
Conover, Cheryl A. , Bale, Laurie K., Stan, Marius N , Stan, Marius N.

The Journal of Clinical Endocrinology & Metabolism | May 15, 2024 | Volume: 109 | Issue: 12 | Pages: 3119-3125

10.1210/clinem/dgae339 | PMID 38752390 Get It

Abstract Context Proptosis in thyroid eye disease (TED) can result in facial disfigurement and visual dysfunction. Treatment with insulin-like growth factor I receptor (IGF-IR) inhibitors has been shown to be effective in reducing proptosis but with side effects. Objective To test the hypothesis that inhibition of IGF-IR indirectly and more selectively with PAPP-A inhibitors attenuates IGF-IR signaling in TED. Informed consent was obtained from patients with TED undergoing surgery, and retro-orbital tissue was collected for fibroblast isolation and culture. Operations were performed in Mayo Clinic operating suites. Cell culture was performed in a sterile tissue culture facility. Retro-orbital tissue was collected from 19 patients with TED. Methods Treatment of TED fibroblasts with proinflammatory cytokines. Flow separation of CD34− and CD34+ orbital fibroblasts, the latter representing infiltrating fibrocytes into the orbit in TED. PAPP-A expression and proteolytic activity, IGF-I stimulation of phosphatidylinositol 3 kinase/Akt pathway, and inhibition by immuno-neutralizing antibodies against PAPP-A, CD34+ status, and associated PAPP-A and IGF-IR expression were measured. Results Proinflammatory cytokines markedly increased PAPP-A expression in TED fibroblasts. IGF-IR expression was not affected by cytokine treatment. Inhibition of PAPP-A's proteolytic activity suppressed IGF-IR activation in orbital fibroblasts from patients with TED. TED fibroblasts that were CD34+ represented ∼80% of the cells in culture and accounted for ∼70% of PAPP-A and IGF-IR–expressing cells. Conclusion These results support a role for PAPP-A in TED pathogenesis and indicate the potential for novel therapeutic targeting of the IGF axis.
Cross-Sectional Associations of Peripheral Hearing, Brain Imaging, and Cognitive Performance With Speech-in-Noise Performance: The Aging and Cognitive Health Evaluation in Elders Brain Magnetic Resonance Imaging Ancillary Study
Jiang, Kening , Albert, Marilyn , Pankow, James S. , Pike, James Russell , Reed, Nicholas S. , Sharrett, A. Richey, Lin, Frank R. , Study, for the ACHIEVE Collaborative, Sanchez, Victoria A , Deal, Jennifer A , Pankow, James S , Pike, James R , Coresh, Josef , Couper, David , Gottesman, Rebecca F. , Hayden, Kathleen M. , Jack, Clifford R. , Knopman, David S. , Mosley, Thomas H. , Sharrett, A. Richey, Deal, Jennifer A. , Study, for the ACHIEVE Collaborative

American Journal of Audiology | May 15, 2024 | Volume: 33 | Issue: 3 | Pages: 683-694

10.1044/2024_aja-23-00108 | PMID 38748919 Get It

Purpose: Population-based evidence in the interrelationships among hearing, brain structure, and cognition is limited. This study aims to investigate the cross-sectional associations of peripheral hearing, brain imaging measures, and cognitive function with speech-in-noise performance among older adults. Method: We studied 602 participants in the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) brain magnetic resonance imaging (MRI) ancillary study, including 427 ACHIEVE baseline (2018–2020) participants with hearing loss and 175 Atherosclerosis Risk in Communities Neurocognitive Study Visit 6/7 (2016–2017/2018–2019) participants with normal hearing. Speech-in-noise performance, as outcome of interest, was assessed by the Quick Speech-in-Noise (QuickSIN) test (range: 0–30; higher = better). Predictors of interest included (a) peripheral hearing assessed by pure-tone audiometry; (b) brain imaging measures: structural MRI measures, white matter hyperintensities, and diffusion tensor imaging measures; and (c) cognitive performance assessed by a battery of 10 cognitive tests. All predictors were standardized to z scores. We estimated the differences in QuickSIN associated with every standard deviation ( SD ) worse in each predictor (peripheral hearing, brain imaging, and cognition) using multivariable-adjusted linear regression, adjusting for demographic variables, lifestyle, and disease factors (Model 1), and, additionally, for other predictors to assess independent associations (Model 2). Results: Participants were aged 70–84 years, 56% female, and 17% Black. Every SD worse in better-ear 4-frequency pure-tone average was associated with worse QuickSIN (−4.89, 95% confidence interval, CI [−5.57, −4.21]) when participants had peripheral hearing loss, independent of other predictors. Smaller temporal lobe volume was associated with worse QuickSIN, but the association was not independent of other predictors (−0.30, 95% CI [−0.86, 0.26]). Every SD worse in global cognitive performance was independently associated with worse QuickSIN (−0.90, 95% CI [−1.30, −0.50]). Conclusions: Peripheral hearing and cognitive performance are independently associated with speech-in-noise performance among dementia-free older adults. The ongoing ACHIEVE trial will elucidate the effect of a hearing intervention that includes amplification and auditory rehabilitation on speech-in-noise understanding in older adults. Supplemental Material: https://doi.org/10.23641/asha.25733679
Beyond the AJR: PET/MRI Using 68Ga-RM2 Has Superior Performance to MRI Alone in the Localization of Lesions in Patients With Biochemical Failure After Prostate Cancer Treatment
Savir-Baruch, Bital , Parent, Ephraim, Parent, Ephraim E.

American Journal of Roentgenology | May 15, 2024 | Volume: 224 | Issue: 1 | Pages: No page available

10.2214/ajr.24.31412 | PMID 38748727 Get It

D19. Accuracy of Preoperative Imaging in Assessing the Involvement of the Deep Periosteal Margin in Dermatofibrosarcoma Protuberans of the Scalp: The Mayo Clinic Experience
Cherukuri, Sai , Zheng, Eugene, Brewer, Jerry D., Bite, Uldis, Guérin, J. , Mardini, Samir , Gibreel, Waleed

Plastic and Reconstructive Surgery - Global Open | May 15, 2024 | Volume: 12 | Issue: S5 | Pages: 77-78

10.1097/01.gox.0001018580.52533.fa Get It

Palliative Care for Patients With Cancer: ASCO Guideline Update
Sanders, Justin J. , Temin, Sarah , Ghoshal, Arunangshu , Alesi, Erin R. , Ali, Zipporah , Chauhan, Cynthia, Cleary, James F. , Firn, Janice , Jones, J , Litzow, Mark R. , Lundquist, Debra , Mardones, Mabel Alejandra, Rabow, Michael W. , Rosa, William E. , Ghoshal, Arun , Ali, Zipporah Vunoro , Epstein, Andrew S , Jones, Joshua A , Litzow, Mark R. , Lundquist, Debra , Nipp, Ryan , Rosa, William E , Zimmermann, Camilla , FERRELL, BETTY ROLLING , Nipp, Ryan David

Journal of Clinical Oncology | May 15, 2024 | Volume: 42 | Issue: 19 | Pages: 2336-2357

10.1200/jco.24.00542 | PMID 38748941 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE To provide evidence-based guidance to oncology clinicians, patients, nonprofessional caregivers, and palliative care clinicians to update the 2016 ASCO guideline on the integration of palliative care into standard oncology for all patients diagnosed with cancer. METHODS ASCO convened an Expert Panel of medical, radiation, hematology-oncology, oncology nursing, palliative care, social work, ethics, advocacy, and psycho-oncology experts. The Panel conducted a literature search, including systematic reviews, meta-analyses, and randomized controlled trials published from 2015-2023. Outcomes of interest included quality of life (QOL), patient satisfaction, physical and psychological symptoms, survival, and caregiver burden. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 52 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations address the integration of palliative care in oncology. Oncology clinicians should refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams that provide outpatient and inpatient care beginning early in the course of the disease, alongside active treatment of their cancer. For patients with cancer with unaddressed physical, psychosocial, or spiritual distress, cancer care programs should provide dedicated specialist palliative care services complementing existing or emerging supportive care interventions. Oncology clinicians from across the interdisciplinary cancer care team may refer the caregivers (eg, family, chosen family, and friends) of patients with cancer to palliative care teams for additional support. The Expert Panel suggests early palliative care involvement, especially for patients with uncontrolled symptoms and QOL concerns. Clinicians caring for patients with solid tumors on phase I cancer trials may also refer them to specialist palliative care. Additional information is available at www.asco.org/supportive-care-guidelines .
Cumulative Deficits Frailty Index and Relationship Status Predict Survival in Multiple Myeloma
Kumar, Shaji , Abdallah, Nadine , Dizona, Paul, LaPlant, Betsy, Terri, Menser, Aug, Sarah, Weivoda, Megan , Buadi, Francis K. , Warsame, Rahma , Lacy, Martha Q. , Hayman, Suzanne R. , Buadi, Francis K , Kumar, Amanika , Dispenzieri, Angela , Cook, Joselle , Gertz, Morie A. , Rajkumar, S. Vincent

No container title available | May 15, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4373874/v1 Get It

AbstractSeveral tools exist for assessing frailty in multiple myeloma (MM), but most are based on clinical trial datasets. In this study, we evaluate the prognostic impact of frailty based on the cumulative deficit frailty index (FI), and the prognostic impact of relationship and socioeconomic status (SES) in newly diagnosed MM patients. This is a retrospective study including 515 patients with MM seen at Mayo Clinic (Rochester, MN) at diagnosis between 2005–2018. The FI was calculated using patient-reported data on activities of daily living and comorbidity data. Items were scored as 0/0.5/1, with 1 indicating deficit. The FI was calculated by adding individual scores and dividing that by the number of non-missing items. Frailty was defined as FI ≥ 0.15; 61% were non-frail and 39% were frail. Frailty and non-married/relationship status were associated with higher disease stage, decreased likelihood of early transplantation, and independently associated with decreased survival. SES was not independently associated with survival. Frail patients reported worse scores for fatigue, pain, and quality of life. In conclusion, a cumulative deficit FI was associated with higher symptom burden and decreased survival in a real-world cohort of newly diagnosed MM patients. Social support has prognostic value and should be assessed in clinical practice.
National Emergency Tele-Critical Care in a Pandemic: Barriers and Solutions
Pamplin, Jeremy , Gray, B.A. Mitchell, Quinn, Matthew , Little, Jeanette R , Subramanian, Sanjay , Farmer, Joseph C. , Ries, Michael, Scott, Benjamin , Participants, for the Governance Stakeholder Working Group and National Emergency Tele-Critical Care Network Team, Armaignac, Donna Lee , Polk, Travis M. , Colombo, Christopher J. , Participants, for the Governance Stakeholder Working Group and National Emergency Tele-Critical Care Network Team

Critical Care Explorations | May 15, 2024 | Volume: 6 | Issue: 5 | Pages: e1091

10.1097/cce.0000000000001091 | PMID 38746740 Get It

The COVID-19 pandemic caused tremendous disruption to the U.S. healthcare system and nearly crippled some hospitals during large patient surges. Limited ICU beds across the country further exacerbated these challenges. Telemedicine, specifically tele-critical care (TCC), can expand a hospital’s clinical capabilities through remote expertise and increase capacity by offloading some monitoring to remote teams. Unfortunately, the rapid deployment of telemedicine, especially TCC, is constrained by multiple barriers. In the summer of 2020, to support the National Emergency Tele-Critical Care Network (NETCCN) deployment, more than 50 national leaders in applying telemedicine technologies to critical care assembled to provide their opinions about barriers to NETCCN implementation and strategies to overcome them. Through consensus, these experts developed white papers that formed the basis of this article. Herein, the authors share their experience and propose multiple solutions to barriers presented by laws, local policies and cultures, and individual perspectives according to a minimum, better, best paradigm for TCC delivery in the setting of a national disaster. Cross-state licensure and local privileging of virtual experts were identified as the most significant barriers to rapid deployment of services, whereas refining the model of TCC to achieve the best outcomes and defining the best financial model is the most significant for long-term success. Ultimately, we conclude that a rapidly deployable national telemedicine response system is achievable.
Biochemical Variability of Nasal Cartilages: Implications in Functional Rhinoplasty
Kim, Sulgi , Mims, Mark M. , Menapace, Denna C. , Shockley, W. , Clark, J. Madison , Kim, Sul Gi , Clark, J Madison , Stack, Taylor

The Laryngoscope | May 15, 2024 | Volume: 134 | Issue: 10 | Pages: 4252-4258

10.1002/lary.31480 | PMID 38747457 Get It

IntroductionNasal valve compromise is a common issue for patients presenting to an otolaryngologist. Anatomically, the dorsal septal cartilage (DSA) articulates with the upper lateral nasal cartilage (ULC). When the ULC weakens, it is prone to collapse and may result in nasal obstruction. Our objectives were to analyze histological differences between quadrangular and DSA nasal cartilages and compare histological composition of these tissues among patients with diagnosis of nasal valve compromise (NVC) versus those without NVC (no NVC).MethodsProspective cross‐sectional study of nasal cartilages from seventy‐three (73) live donors. Quadrangular cartilage (QC), and DSA from patients undergoing septorhinoplasty were collected. Safranin O histochemical staining was used to observe glycosaminoglycans (GAGs) content and cell count. Masson's Trichrome staining was used to assess collagen content in these nasal cartilages.ResultsMean GAG content was lower in DSA compared with QUAD cartilage (68.18% vs. 87.22%, p < 0.0001), and was lowest in DSA of patients with NVC (59.07%). Mean collagen content was higher in DSA compared with QUAD cartilage, (65.43% vs. 46.65%, p = 0.0002), and was highest in DSA of patients with NVC (74.86%).ConclusionThe DSA showed decreased GAG and increased collagen content compared with quadrangular cartilage. Within the DSA subsite, patients with presurgical NVC had the lowest GAG and highest collagen levels. This observation suggests that the biochemical composition of the DSA may contribute to its weakening, potentially resulting in its inability to withstand minor trauma and/or the effects of aging, ultimately leading to NVC.Level of EvidenceN/A Laryngoscope, 134:4252–4258, 2024
Association of Posterior Tibial Slope With Outcomes After Multiligamentous Knee Reconstruction for Knee Dislocation Grades 2 to 4
Conyer, Ryan T. , Wang, Allen S. , Okoroha, Kelechi R. , Levy, Bruce A. , Langhans, Mark T. , Wang, Allen , Krych, Aaron J. , Hevesi, Mario , Stuart, Michael J.

Orthopaedic Journal of Sports Medicine | May 15, 2024 | Volume: 12 | Issue: 5 | Pages: No page available

10.1177/23259671241249473 | PMID 38757069 Get It

Background: Patients with isolated anterior cruciate ligament (ACL) reconstruction have demonstrated an increased risk of ACL graft failure and lower patient-reported outcome (PRO) scores when increased posterior tibial slope (PTS) is present. However, there is a paucity of literature evaluating the effect of PTS on outcomes after combined bicruciate multiligamentous knee reconstruction. Purpose: To determine whether differences exist for graft failure rates or PRO scores based on PTS after combined bicruciate multiligamentous knee reconstruction. Study Design: Cohort study; Level of evidence, 3. Methods: All patients who underwent combined ACL and posterior cruciate ligament (PCL) reconstruction between 2000 and 2020 at our institution were identified. Exclusion criteria were age <18 years, knee dislocation grade 5 injuries, concomitant osteotomy procedures, and <2 years of clinical follow-up. Demographic and outcomes data were collected from our prospectively gathered multiligamentous knee injury database. Lysholm and International Knee Documentation Committee (IKDC) scores were analyzed in relation to PTS. Outcomes were compared for patients with a PTS above and below the mean for the total cohort, PTS >12° versus <12°, positive versus negative Lachman test at follow-up, and positive versus negative posterior drawer test at follow-up. Results: A total of 98 knees in 98 patients were included in the study, with a mean clinical follow-up of 5.1 years (median, 4.6 years; range, 2-16 years). The mean PTS was 8.7° (range, 0.4°-16.9°). Linear regression analysis showed no significant correlation between PTS and IKDC or Lysholm scores. Patients with a PTS above the mean of 8.7° trended toward lower IKDC ( P = .08) and Lysholm ( P = .06) scores. Four patients experienced ACL graft failure and 5 patients experienced PCL graft failure. There were no differences in graft failure rates or PRO scores for patients with a PTS >12°. Patients with a positive Lachman test trended toward higher PTS (9.6° vs 8.5°, P = .15). Conclusion: In this series of bicruciate multiligamentous knee reconstructions at midterm follow-up, no differences in graft failures, complications, reoperations, revisions, or PRO scores based on PTS were identified. Patients with a positive Lachman test were found to have a slightly higher PTS, although this did not reach statistical significance.